New drug combo for advanced bile duct cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug called QLS31905 combined with chemotherapy, with or without another drug QL2107, for people with advanced bile duct cancer that has not been treated before. It aims to see if these combinations are safe and help shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have bile duct cancer that has spread or cannot be removed by surgery.
- You have at least one tumor that can be measured on scans.
- You have not had any previous treatment for advanced bile duct cancer (like chemotherapy or targeted therapy).
- You are not allergic to any of the study drugs or their ingredients.
- You have not had another type of cancer in the last 5 years (except for some skin cancers).
- You have not had serious bleeding in the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two experimental drugs (QLS31905 and QL2107) plus chemotherapy (oxaliplatin and capecitabine) as the first treatment for advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. The goal is to see if the combination helps shrink tumors and control the cancer better than standard care.
This trial tests a combination of two new study drugs (QLS31905 and QL1706) plus chemotherapy against advanced solid tumors that have a specific protein called Claudin18.2. It's for people who have not had any prior treatment for their advanced cancer.
This trial is testing whether a new drug (SHR-8068) combined with adebrelimab and chemotherapy works better than the current standard treatment for people with advanced bile duct cancer who have not been treated yet.
This trial tests a new drug called QLS5132, alone or in combination, for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it can shrink tumors or slow their growth.
This trial tests a new drug combination (LBL-024) for people with advanced solid tumors, including bile duct and liver cancers. It aims to see if the treatment is safe and effective for those who have not responded to other therapies.
This study tests a combination of three drugs (gemcitabine, cisplatin, nab-paclitaxel) plus an immunotherapy (tislelizumab) for people with advanced biliary tract cancer who haven't had treatment yet. The goal is to see if this cocktail shrinks tumors better than standard care.
Hear when a new CLDN18.2-positive Advanced Biliary Tract Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.